Arabic Arabic English English French French German German
dark

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells

CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia. It modifies a patient’s own T-cells by adding a piece of an antibody that recognizes unique features on the surface of cancer cells. In a new study, researchers report that they have dramatically broadened the potential targets of this approach – their engineered T-cells attack a variety of solid-tumor cancer cells from humans and mice.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by HFACULTY News. Publisher: Top Health News — ScienceDaily Click this link to read the full content from the Publisher Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

MHRA guidance on coronavirus (COVID-19)

Next Post

Clostridium difficile: Fecal microbial transplantation more effective and less costly than antibiotics

Related Posts
Total
0
Share